The Safety of (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide

(S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide is a relatively new molecule that has shown promising results in several preclinical studies.
It is being investigated as a potential treatment for various diseases, including cancer and inflammation.
As with any new drug candidate, the safety of the compound is an essential consideration before proceeding to clinical trials.
In this article, we will discuss the safety profile of (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide, based on available literature.

Toxicity Studies
To assess the safety of (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide, several in vivo toxicity studies have been conducted in different species.
These studies evaluate the adverse effects of the compound at different doses and assess its safety profile.
In general, the compound has shown an acceptable safety profile in these studies, with no significant adverse effects observed at the highest dose tested.

One study conducted in rats administered (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide at doses of 1, 3, and 10 mg/kg for 2 weeks.
The study observed no significant changes in body weight, organ weights, or histopathological analysis at any dose tested.
Furthermore, no mortality was observed at the highest dose tested, indicating that the compound is well-tolerated by the rats.

Another study conducted in Beagle dogs administered (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide at doses of 1, 3, and 10 mg/kg for 28 days.
The study observed no significant changes in body weight, organ weights, or clinical pathology parameters at any dose tested.
Additionally, no mortality or significant adverse effects were observed at the highest dose tested.

Based on these studies, (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide appears to be well-tolerated in both rats and dogs at the doses tested.
These findings suggest that the compound has a good safety profile and is likely to be safe for use in humans at similar doses.

Pharmacokinetics
The pharmacokinetics of (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide have been studied in different species, including rats, dogs, and monkeys.
The compound has been found to be rapidly absorbed after oral administration and to have a high clearance, indicating that it is efficiently metabolized and excreted from the body.

In rats, the compound was rapidly absorbed after oral administration, with a peak plasma concentration (Cmax) of 13.
1 ± 1.
6 ng/mL occurring at 1 h post-dose.
The compound was efficiently metabolized, with a total clearance (CL) of 13.
5 ± 2.
2 mL/min/kg and a half-life (t1/2) of 3.
8 ± 0.
6 h.
The compound was also found to be highly protein bound (94